Nod-like receptor pyrin containing 3 (NLRP3) in the post-mortem frontal cortex from patients with bipolar disorder: A potential mediator between mitochondria and immune-activation

Journal of Psychiatric Research

Volumn 72, Issue , 2016, Pages 43-50

  Kim, Helena Kyunghee ^a   Andreazza, Ana Cristina ^a,b   Elmi, Nika ^a   Chen, Wenjun ^a   Young, L Trevor ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Bipolar disorder; Complex I; Frontal cortex; NLRP3; Oxidative stress; Post mortem brain

Indexed keywords

APOPTOSIS ASSOCIATED SPECK LIKE PROTEIN; CRYOPYRIN; CYTOCHROME C OXIDASE; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; NDUFS7 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); TUMOR NECROSIS FACTOR ALPHA; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; CARRIER PROTEIN; CYTOSKELETON PROTEIN; IL10 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; NLRP3 PROTEIN, HUMAN; PYCARD PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BRAIN HOMOGENATE; CELL FRACTIONATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SCHIZOPHRENIA; VERY ELDERLY; WESTERN BLOTTING; AGING; FRONTAL LOBE; METABOLISM; MIDDLE AGED;

AGED; AGED, 80 AND OVER; AGING; BIPOLAR DISORDER; CARRIER PROTEINS; CASPASE 1; CYTOSKELETAL PROTEINS; FEMALE; FRONTAL LOBE; HUMANS; INFLAMMASOMES; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MITOCHONDRIA; SCHIZOPHRENIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84949204713     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.10.015     Document Type: Article

References (85)

1. Andreazza A.C., Frey B.N., Erdtmann B., Salvador M., Rombaldi F., Santin A., Goncalves C.A., Kapczinski F. DNA damage in bipolar disorder. Psychiatry Res. 2007, 153:27-32.
2. Andreazza A.C., Kapczinski F., Kauer-Sant'Anna M., Walz J.C., Bond D.J., Goncalves C.A., Young L.T., Yatham L.N. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J. Psychiatry Neurosci. 2009, 34:263-271.
3. Andreazza A.C., Kauer-Sant'anna M., Frey B.N., Bond D.J., Kapczinski F., Young L.T., Yatham L.N. Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect Disord. 2008, 111:135-144.
4. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch. Gen. Psychiatry 2010, 67:360-368.
5. Andreazza A.C., Wang J.F., Salmasi F., Shao L., Young L.T. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J. Neurochem. 2013, 127(4):552-561.
6. Banigan M.G., Kao P.F., Kozubek J.A., Winslow A.R., Medina J., Costa J., Schmitt A., Schneider A., Cabral H., Cagsal-Getkin O., Vanderburg C.R., Delalle I. Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS One 2013, 8:e48814.
7. Barbosa I.G., Huguet R.B., Mendonça V.A., Sousa L.P., Neves F.S., Bauer M.E., Teixeira A.L. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261:139-143.
8. Bashkatova V., Alam M., Vanin A., Schmidt W.J. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp. Neurol. 2004, 186:235-241.
9. Berk M., Berk L., Dodd S., Cotton S., Macneil C., Daglas R., Conus P., Bechdolf A., Moylan S., Malhi G.S. Stage managing bipolar disorder. Bipolar Disord. 2013, 16(5):471-477.
10. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., Norman T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. 2007, 41-49.
11. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yücel M., Gama C.S., Dodd S., Dean B., Magalhães P.V., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav Rev. 2011, 35:804-817.
12. Bresee C., Rapaport M.H. Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int. J. Neuropsychopharmacol. 2009, 12:861-865.
13. Brown N.C., Andreazza A.C., Young L.T. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014, 218:61-68.
14. Bryan N.B., Dorfleutner A., Kramer S.J., Yun C., Rojanasakul Y., Stehlik C. Differential splicing of the apoptosis-associated speck like protein containing a caspase recruitment domain (ASC) regulates inflammasomes. J. Inflamm. (Lond) 2010, 7:23.
15. Chandana R., Mythri R.B., Mahadevan A., Shankar S.K., Srinivas Bharath M.M. Biochemical analysis of protein stability in human brain collected at different post-mortem intervals. Indian J. Med. Res. 2009, 129:189-199.
16. Chanput W., Mes J.J., Wichers H.J. THP-1 cell line: an in vitro cell model for immune modulation approach. Int. Immunopharmacol. 2014, 23(1):37-45.
17. Clay H.B., Sillivan S., Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int. J. Dev. Neurosci. 2010, 29:311-324.
18. Cooper A.J., Kristal B.S. Multiple roles of glutathione in the central nervous system. Biol. Chem. 1997, 378:793-802.
19. Cui J., Shao L., Young L.T., Wang J.F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007, 144:1447-1453.
20. Dean B., Gibbons A.S., Tawadros N., Brooks L., Everall I.P., Scarr E. Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders. Mol. Psychiatry 2013, 18:767-773.
21. Dheen S.T., Kaur C., Ling E.A. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 2007, 14:1189-1197.
22. Dringen R. Glutathione metabolism and oxidative stress in neurodegeneration. Eur. J. Biochem. 2000, 267:4903.
23. Eder C. Mechanisms of interleukin-1beta release. Immunobiology 2009, 214:543-553.
24. Felger J.C., Li L., Marvar P.J., Woolwine B.J., Harrison D.G., Raison C.L., Miller A.H. Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav. Immun. 2013, 31:153-160.
25. Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front. Neuroendocrinol. 2012, 33:315-327.
26. Fineberg A.M., Ellman L.M. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 2013, 73:951-966.
27. Frey B.N., Stanley J.A., Nery F.G., Monkul E.S., Nicoletti M.A., Chen H.H., Hatch J.P., Caetano S.C., Ortiz O., Kapczinski F., Soares J.C. Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo 1H MRS study. Bipolar Disord. 2007, 9(Suppl. 1):119-127.
28. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 2011, 14:123-130.
29. Gracie J.A., Robertson S.E., McInnes I.B. Interleukin-18. J. Leukoc. Biol. 2003, 73:213-224.
30. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 1992, 59:1609-1623.
31. Halliwell B. Biochemistry of oxidative stress. Biochem. Soc. Trans. 2007, 35:1147-1150.
32. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 2007, Clarendon Press, Oxford. 4 ed.
33. Hanamsagar R., Torres V., Kielian T. Inflammasome activation and IL-1β/IL-18 processing are influenced by distinct pathways in microglia. J. Neurochem. 2011, 119:736-748.
34. Iwamoto K., Bundo M., Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum. Mol. Genet. 2005, 14:241-253.
35. Janssen R.J., Nijtmans L.G., van den Heuvel L.P., Smeitink J.A. Mitochondrial complex I: structure, function and pathology. J. Inherit. Metab. Dis. 2006, 29:499-515.
36. Jarskog L.F. Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations. Curr. Opin. Psychiatry 2006, 19:307-312.
37. Karry R., Klein E., Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry 2004, 55:676-684.
38. Kato T., Takahashi S., Shioiri T., Inubushi T. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J. Affect Disord. 1993, 27:53-59.
39. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Young L.T., Yatham L.N. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 2009, 12:447-458.
40. Kenney M.C., Chwa M., Atilano S.R., Falatoonzadeh P., Ramirez C., Malik D., Tarek M., Cáceres-del-Carpio J., Nesburn A.B., Boyer D.S., Kuppermann B.D., Vawter M., Jazwinski S.M., Miceli M., Wallace D.C., Udar N. Inherited mitochondrial DNA variants can affect complement, inflammation and apoptosis pathways: insights into mitochondrial-nuclear interactions. Hum. Mol. Genet. 2014, 23:3537-3551.
41. Kim H.K., Andreazza A.C. The relationship between oxidative stress and post-translational modification of the dopamine transporter in bipolar disorder. Expert Rev. Neurother. 2012, 12:849-859.
42. Kim H.K., Andreazza A.C., Yeung P.Y., Isaacs-Trepanier C., Young L.T. Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. J. Psychiatry Neurosci. 2014, 39:276-285.
43. Kim H.K., Chen W., Andreazza A.C. The potential role of the NLRP3 inflammasome as a link between mitochondrial complex I dysfunction and inflammation in bipolar disorder. Neural Plast. 2015, 2015:408136.
44. Kim H.W., Rapoport S.I., Rao J.S. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol. Psychiatry 2011, 16:419-428.
45. Kim Y.K., Jung H.G., Myint A.M., Kim H., Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect Disord. 2007, 104:91-95.
46. Konradi C., Eaton M., MacDonald M.L., Walsh J., Benes F.M., Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry 2004, 61:300-308.
47. Konradi C., Sillivan S.E., Clay H.B. Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol. Dis. 2012, 45:37-47.
48. Konradi C., Zimmerman E.I., Yang C.K., Lohmann K.M., Gresch P., Pantazopoulos H., Berretta S., Heckers S. Hippocampal interneurons in bipolar disorder. Arch. Gen. Psychiatry 2011, 68:340-350.
49. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., Kupfer D.J. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J. Affect Disord. 2012, 141:1-10.
50. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J.A., Robinson J.P. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 2003, 278:8516-8525.
51. Libíková H., Breier S., Kocisová M., Pogády J., Stünzner D., Ujházyová D. Assay of interferon and viral antibodies in the cerebrospinal fluid in clinical neurology and psychiatry. Acta Biol. Med. Ger. 1979, 38:879-893.
52. López-Armada M.J., Riveiro-Naveira R.R., Vaamonde-García C., Valcárcel-Ares M.N. Mitochondrial dysfunction and the inflammatory response. Mitochondrion 2013, 13:106-118.
53. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29:141-152.
54. Mamdani F., Rollins B., Morgan L., Sequeira P.A., Vawter M.P. The somatic common deletion in mitochondrial DNA is decreased in schizophrenia. Schizophr. Res. 2014, 159:370-375.
55. Maurer I., Zierz S., Moller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 2001, 48:125-136.
56. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
57. Morris G., Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab. Brain Dis. 2014, 29:19-36.
58. Moylan S., Berk M., Dean O.M., Samuni Y., Williams L.J., O'Neil A., Hayley A.C., Pasco J.A., Anderson G., Jacka F.N., Maes M. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci. Biobehav Rev. 2014, 45:46-62.
59. Munkholm K., Braüner J.V., Kessing L.V., Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J. Psychiatr. Res. 2013, 47:1119-1133.
60. Müller N., Myint A.M., Schwarz M.J. Inflammation in schizophrenia. Adv. Protein Chem. Struct. Biol. 2012, 88:49-68.
61. Nascimento C., Kim H.K., Young L.T., Mendonça K.M., Grinberg L.T., Lafer B., Andreazza A.C. Glutathione-mediated effects of lithium in decreasing protein oxidation induced by mitochondrial complex I dysfunction. J. Neural Transm. 2014, 122(6):741-746.
62. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008, 11:851-876.
63. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect Disord. 2006, 90:263-267.
64. Perregaux D., Gabel C.A. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 1994, 269:15195-15203.
65. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010, 15:384-392.
66. Rao J.S., Kellom M., Reese E.A., Rapoport S.I., Kim H.W. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J. Affect Disord. 2012, 136:63-71.
67. Savas H.A., Gergerlioglu H.S., Armutcu F., Herken H., Yilmaz H.R., Kocoglu E., Selek S., Tutkun H., Zoroglu S.S., Akyol O. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J. Biol. Psychiatry 2006, 7:51-55.
68. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
69. Scola G., Kim H.K., Young L.T., Andreazza A.C. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol. Psychiatry 2012, 73(2):e4-5.
70. Scola G., Kim H.K., Young L.T., Andreazza A.C. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol. Psychiatry 2013, 73:e4-5.
71. Sequeira A., Rollins B., Magnan C., van Oven M., Baldi P., Myers R.M., Barchas J.D., Schatzberg A.F., Watson S.J., Akil H., Bunney W.E., Vawter M.P. Mitochondrial mutations in subjects with psychiatric disorders. PLoS One 2015, 10:e0127280.
72. Sheng G., Demers M., Subburaju S., Benes F.M. Differences in the circuitry-based association of copy numbers and gene expression between the hippocampi of patients with schizophrenia and the hippocampi of patients with bipolar disorder. Arch. Gen. Psychiatry 2012, 69:550-561.
73. Shimada K., Crother T.R., Karlin J., Dagvadorj J., Chiba N., Chen S., Ramanujan V.K., Wolf A.J., Vergnes L., Ojcius D.M., Rentsendorj A., Vargas M., Guerrero C., Wang Y., Fitzgerald K.A., Underhill D.M., Town T., Arditi M. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36:401-414.
74. Sies H. Oxidative stress: from basic research to clinical application. Am. J. Med. 1991, 91:31S-38S.
75. Sollberger G., Strittmatter G.E., Garstkiewicz M., Sand J., Beer H.D. Caspase-1: the inflammasome and beyond. Innate Immun. 2014, 20:115-125.
76. Sorbara M.T., Girardin S.E. Mitochondrial ROS fuel the inflammasome. Cell Res. 2011, 21:558-560.
77. Sun X., Wang J.F., Tseng M., Young L.T. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J. Psychiatry Neurosci. 2006, 31:189-196.
78. Söderlund J., Olsson S.K., Samuelsson M., Walther-Jallow L., Johansson C., Erhardt S., Landén M., Engberg G. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J. Psychiatry Neurosci. 2011, 36:114-118.
79. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat. Rev. Immunol. 2010, 10:210-215.
80. Vawter M.P., Tomita H., Meng F., Bolstad B., Li J., Evans S., Choudary P., Atz M., Shao L., Neal C., Walsh D.M., Burmeister M., Speed T., Myers R., Jones E.G., Watson S.J., Akil H., Bunney W.E. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol. Psychiatry 2006, 11(615):663-679.
81. Wang J.F., Shao L., Sun X., Young L.T. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009, 11:523-529.
82. Weber A., Wasiliew P., Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci. Signal 2010, 3:cm2.
83. Weerasinghe G.R., Rapoport S.I., Bosetti F. The effect of chronic lithium on arachidonic acid release and metabolism in rat brain does not involve secretory phospholipase A2 or lipoxygenase/cytochrome P450 pathways. Brain Res. Bull. 2004, 63:485-489.
84. Wieckowski M.R., Giorgi C., Lebiedzinska M., Duszynski J., Pinton P. Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. Nat. Protoc. 2009, 4:1582-1590.
85. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.